Diabetic macular oedema / Diabetic retinopathy
BREYE: A phase 1b open-label, dose-escalating study evaluating the safety, tolerability, pharmacokinetics and early signs of biological activity of Danegaptide following oral administration in subjects with Diabetic Macular Oedema (DME).
Eye condition/Study type:
Diabetic Macular Oedema (DME)
Principal Investigator:
Miss Christine Kiire
This is a multicentre, sequential-group, open-label, uncontrolled, dose-escalating Phase 1b study assessing the safety, tolerability, pharmacokinetics (PK), metabolite profile, and early signs of biological activity following oral administration of danegaptide in participants diagnosed with Diabetic Macular Oedema. A total of 4 cohorts are planned to explore escalating doses (75 and 150 mg) and/or different dosing frequencies (once and twice daily) of danegaptide. Cohort 1: 75 mg once daily; Cohort 2: 75 mg twice daily; Cohort 3: 150 mg once daily; Cohort 4: 150 mg twice daily.
https://studies.ouh.nhs.uk/project_detail/9529/
Currently recruiting. If interested, please contact via email ERGO@ouh.nhs.uk
VOYAGER Study: Real-World, long-term data collection to gain clinical insights into Roche ophthalmology products
Eye condition/Study type:
Neovascular age-related macular degeneration (wet AMD) or Diabetic macular oedema
Principal Investigator:
Miss Christine Kiire
This study will explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products approved in retinal indications in real-world, routine clinical practice.
https://studies.ouh.nhs.uk/project_detail/9760/
Contact ERGO@ouh.nhs.uk if you have any questions.